Roll Call reports that three patient advocacy groups are “challenging a Trump-era rule that allows insurers to prevent financial assistance from drug companies from counting toward a patient’s annual out-of-pocket costs.” Insurers “argue that drug companies’ copay assistance programs allow drug companies to steer patients toward expensive brand-name drugs, driving up health costs for everyone.” However, in a lawsuit targeting HHS filed Tuesday, the advocacy groups “argue that the rule disproportionately impacts people with chronic diseases, like diabetes and HIV, that require the use of costly drugs.”

From the news release of the American Association for Justice.